Biopharmx Corp (NYSEAMERICAN:BPMX) was the recipient of a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 10,443,253 shares, a decline of 3.3% from the February 15th total of 10,797,776 shares. Based on an average daily volume of 23,306,239 shares, the days-to-cover ratio is presently 0.4 days. Currently, 59.7% of the company’s stock are short sold.

In other Biopharmx news, major shareholder Vivo Capital Viii, Llc sold 2,000,000 shares of the business’s stock in a transaction dated Wednesday, March 7th. The stock was sold at an average price of $0.36, for a total value of $720,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

An institutional investor recently bought a new position in Biopharmx stock. Armistice Capital LLC bought a new position in Biopharmx Corp (NYSEAMERICAN:BPMX) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 3,470,000 shares of the biotechnology company’s stock, valued at approximately $382,000. Armistice Capital LLC owned about 2.72% of Biopharmx as of its most recent filing with the SEC.

Separately, Maxim Group reissued a “buy” rating and issued a $1.50 target price on shares of Biopharmx in a research report on Friday, December 8th.

Biopharmx (NYSEAMERICAN:BPMX) opened at $0.33 on Friday. Biopharmx has a 52-week low of $0.10 and a 52-week high of $0.90. The firm has a market capitalization of $45.42, a PE ratio of -1.21 and a beta of 0.43.

Biopharmx (NYSEAMERICAN:BPMX) last issued its earnings results on Thursday, December 7th. The biotechnology company reported ($0.05) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.05). The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.03 million.

ILLEGAL ACTIVITY NOTICE: “Short Interest in Biopharmx Corp (BPMX) Declines By 3.3%” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at

About Biopharmx

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with's FREE daily email newsletter.